We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+10.09%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$176M
AUM Growth
+$4.87M
Cap. Flow
-$868K
Cap. Flow %
-0.49%
Top 10 Hldgs %
54.6%
Holding
85
New
17
Increased
11
Reduced
21
Closed
12

Top Buys

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$3.05M
2
CMPS
Compass Pathways
CMPS
+$2.52M
3
ENGN icon
enGene Therapeutics
ENGN
+$2.23M
4
RLMD icon
Relmada Therapeutics
RLMD
+$1.94M
5
CLDX icon
Celldex Therapeutics
CLDX
+$1.91M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$3.6M
2
KLAC icon
KLA
KLAC
+$2.93M
3
CSTL icon
Castle Biosciences
CSTL
+$2.22M
4
IMNM icon
Immunome
IMNM
+$1.78M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 73.14%
2 Technology 21.04%
3 Energy 4.89%
4 Materials 0.6%
5 Financials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
51
DELISTED
Apellis Pharmaceuticals
APLS
$563K 0.32%
14,000
– –
IDYA icon
52
IDEAYA Biosciences
IDYA
$3.47B
$562K 0.32%
+16,860
New +$566K
RCUS icon
53
Arcus Biosciences
RCUS
$3.44B
$559K 0.32%
+25,889
New +$559K
RGNX icon
54
Regenxbio
RGNX
$511M
$555K 0.32%
+66,270
New +$696K
KPTI icon
55
Karyopharm Therapeutics
KPTI
$216M
$468K 0.27%
+83,952
New +$640K
RCKT icon
56
Rocket Pharmaceuticals
RCKT
$376M
$455K 0.26%
+127,025
New +$505K
VRDN icon
57
Viridian Therapeutics
VRDN
$1.99B
$393K 0.22%
+20,100
New +$597K
OM icon
58
Outset Medical
OM
$77.9M
$380K 0.22%
98,882
-31
-0% -$127
LUNG icon
59
Pulmonx
LUNG
$59.1M
$323K 0.18%
250,221
-352
-0.1% -$582
CSTL icon
60
Castle Biosciences
CSTL
$733M
$317K 0.18%
12,900
-67,700
-84% -$2.22M
TRIN icon
61
Trinity Capital
TRIN
$1.6B
$294K 0.17%
20,000
– –
CADL icon
62
Candel Therapeutics
CADL
$746M
$294K 0.17%
60,000
– –
VYGR icon
63
Voyager Therapeutics
VYGR
$192M
$289K 0.16%
74,918
– –
CGEM icon
64
Cullinan Oncology
CGEM
$1.09B
$284K 0.16%
20,000
– –
KBDC
65
Kayne Anderson BDC
KBDC
$910M
$274K 0.16%
20,000
– –
GRCE
66
Grace Therapeutics
GRCE
$40.2M
$232K 0.13%
+50,000
New +$196K
ELUT icon
67
Elutia
ELUT
$42M
$173K 0.1%
165,094
-97,924
-37% -$97.8K
KYNB
68
Kyntra Bio
KYNB
$29.3M
$153K 0.09%
+22,566
New +$177K
QNRX
69
Quoin Pharmaceuticals
QNRX
$8.52M
$132K 0.08%
+20,000
New +$181K
PHR icon
70
Phreesia
PHR
$662M
$120K 0.07%
14,300
-96,400
-87% -$1.28M
ZNTL icon
71
Zentalis Pharmaceuticals
ZNTL
$364M
$41K 0.02%
17,503
+503
+3% +$1.3K
DCGO icon
72
DocGo
DCGO
$64.3M
$24.9K 0.01%
39,573
-10,335
-21% -$7.78K
GOSS icon
73
Gossamer Bio
GOSS
$83.2M
$5.97K ﹤0.01%
18,176
-120,000
-87% -$189K
ATEC icon
74
Alphatec Holdings
ATEC
$1.31B
– –
-18,058
Closed -$380K
FOLD
75
DELISTED
Amicus Therapeutics
FOLD
– –
-253,000
Closed -$3.6M
1 2
3
4

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Birchview Capital held 85 positions worth $176M, up 2.8% from $171M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Birchview Capital's Q1 2026 filing shows 17 new, 11 increased, 21 reduced and 12 closed positions. Its largest new stake was Ocular Therapeutix: 320,000 shares worth $2.71M. The largest sale was Amicus Therapeutics, an estimated $3.6M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 76% a quarter earlier, followed by Technology and Energy.

  • Birchview Capital's largest Q1 2026 buy was Ocular Therapeutix: 320,000 shares worth $2.71M.
  • Birchview Capital added most to Pacific Biosciences in Q1 2026, an estimated $1.79M increase.
  • Birchview Capital's biggest Q1 2026 reduction was KLA, cutting an estimated $2.93M.
  • Birchview Capital fully exited Amicus Therapeutics in Q1 2026, selling an estimated $3.6M.
  • Birchview Capital's ten largest holdings make up 55% of its $176M portfolio in Q1 2026.
  • Birchview Capital opened 17 new positions and closed 12 in Q1 2026.
  • Birchview Capital's portfolio value rose 2.8% quarter-over-quarter to $176M.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.